Story

AstraZeneca's Tezspire Succeeds in Late-Stage Esophagus Disease Trial

ENTHMSVIIDZHZH-TWJAKOHI
Aug 27, 20262 min read
AstraZeneca's Tezspire Succeeds in Late-Stage Esophagus Disease Trial
Text size
Background

AstraZeneca announced Thursday that its drug Tezspire, developed in partnership with Amgen, met its primary goals in a late-stage trial for a chronic inflammatory disorder of the esophagus. The positive results offer a needed boost to the pharmaceutical giant's pipeline following several recent clinical setbacks.

Trial Success and Potential Expansion

The trial evaluated Tezspire in patients with eosinophilic esophagitis (EoE), a condition affecting more than 470,000 people in the United States. According to the company's statement, the drug significantly reduced inflammation in the esophagus and eased difficulty in swallowing when compared to a placebo.

Tezspire is a monoclonal antibody that works by blocking TSLP, a protein that can trigger inflammation. The drug is already approved in the U.S. and other markets as an add-on treatment for severe asthma, where it competes with Sanofi and Regeneron's Dupixent. The drug generated $1.13 billion in sales for AstraZeneca in 2025.

Context of Recent Setbacks

The successful trial provides a welcome win for AstraZeneca, which has faced a string of disappointing clinical and regulatory outcomes recently. These challenges are a headwind to CEO Pascal Soriot's goal of reaching $80 billion in annual sales by 2030.

Sample IUX Markets – In-articleAd

Recent setbacks for the company's pipeline include:

  • Wainua: Unexpectedly failed a heart disease trial in July.
  • Ultomiris: A late-stage study for a rare disease failed to meet its goals.
  • Camizestrant: A U.S. regulatory panel rejected the breast cancer drug in May due to trial design concerns.
  • Volrustomig: An advanced study for this experimental lung cancer drug was halted this month.

Market Impact and Outlook

Despite the positive news, AstraZeneca’s shares were down 0.5% in early trading Thursday, according to Reuters. The stock has fallen 14% since the Wainua trial failure was announced in July.

Analysts note that investor focus remains fixed on upcoming results from two major cancer trials, which are viewed as more critical to the company's near-term growth prospects and share price performance. The Tezspire results, while encouraging for expanding the drug's label, have not yet shifted the broader market sentiment.

Read next

More on Stocks
Back to latest news

LATEST